The immunosuppressive activity in the plasma derived from AML patients can be mitigated through the use of small-molecule inhibitors of ARG2 (NOHA), or by supplementing with high levels of arginine [91], direct evidence for the involvement of ARG activity in the circulation to drive immunosuppression. The gene discussed is ARG2; the disease is acute myeloid leukemia.